Solventum Corporation (NYSE:SOLV) Shares Purchased by Achmea Investment Management B.V.

Achmea Investment Management B.V. boosted its position in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 28.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,985 shares of the company's stock after acquiring an additional 4,653 shares during the quarter. Achmea Investment Management B.V.'s holdings in Solventum were worth $1,595,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SOLV. Clarity Asset Management Inc. purchased a new stake in shares of Solventum in the 4th quarter valued at approximately $25,000. Raiffeisen Bank International AG purchased a new position in shares of Solventum during the fourth quarter worth approximately $29,000. Colonial Trust Co SC increased its holdings in shares of Solventum by 240.7% in the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company's stock valued at $34,000 after acquiring an additional 361 shares during the period. Banque Transatlantique SA acquired a new position in shares of Solventum in the 4th quarter valued at $42,000. Finally, EverSource Wealth Advisors LLC raised its position in Solventum by 48.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company's stock valued at $45,000 after purchasing an additional 223 shares during the last quarter.

Solventum Trading Up 0.1%

NYSE:SOLV traded up $0.11 during mid-day trading on Monday, reaching $75.57. The company's stock had a trading volume of 54,027 shares, compared to its average volume of 1,125,118. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.19 and a quick ratio of 0.85. The stock has a market cap of $13.07 billion, a P/E ratio of 35.05, a P/E/G ratio of 1.93 and a beta of 0.54. The company's fifty day simple moving average is $71.48 and its two-hundred day simple moving average is $71.89. Solventum Corporation has a twelve month low of $47.16 and a twelve month high of $100.00.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.19 by $0.15. Solventum had a net margin of 4.55% and a return on equity of 31.01%. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. During the same quarter last year, the business earned $2.08 EPS. Solventum's revenue for the quarter was up 2.7% on a year-over-year basis. On average, equities analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SOLV shares. Mizuho increased their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. Morgan Stanley increased their price objective on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. The Goldman Sachs Group increased their price target on shares of Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday, March 3rd. KeyCorp began coverage on Solventum in a report on Friday, June 6th. They set a "sector weight" rating for the company. Finally, Piper Sandler raised Solventum from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $78.00 to $87.00 in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $80.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.